The estimated Net Worth of Rabia Gurses Ozden is at least $1.39 millió dollars as of 3 February 2024. Dr Ozden owns over 6,346 units of Ocular Therapeutix Inc stock worth over $1,291,776 and over the last 3 years he sold OCUL stock worth over $100,579.
Dr has made over 4 trades of the Ocular Therapeutix Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 6,346 units of OCUL stock worth $30,842 on 3 February 2024.
The largest trade he's ever made was selling 7,764 units of Ocular Therapeutix Inc stock on 31 January 2024 worth over $38,432. On average, Dr trades about 2,136 units every 36 days since 2022. As of 3 February 2024 he still owns at least 153,054 units of Ocular Therapeutix Inc stock.
You can see the complete history of Dr Ozden stock trades at the bottom of the page.
Dr. Rabia Gurses Ozden is the Sr. VP of Clinical Devel. at Ocular Therapeutix Inc.
Dr Ozden is 52, he's been the Sr. VP of Clinical Devel. of Ocular Therapeutix Inc since . There are 13 older and 3 younger executives at Ocular Therapeutix Inc. The oldest executive at Ocular Therapeutix Inc is Richard Lindstrom, 72, who is the Independent Director.
Rabia's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY, CA, 94063.
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer és Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include: